NVCR News and Press, NovoCure Limited From 10/24/22

NovoCure Limited ( NASDAQ: NVCR ), the developer of tumor treating fields (TTFields) devices to treat cancer, reached a four-month low intraday on Monday after Piper Sandler downgraded the company despite positive views on a Phase 3 readout expected in Q1 2023. NVCR advances...

Shares of Novocure (NASDAQ: NVCR) were sinking 10.7% lower as of 11:02 a.m. ET on Monday. The decline came after Piper Sandler analyst Jason Bednar downgraded the stock to neutral from overweight. Bednar also cut the 12-month price target for Novocure to $70 from the previous target...

Highlights include an analysis of predictive biomarkers for overall survival and progression free survival in newly diagnosed glioblastoma patients Pre-clinical research shows the potential for improved tumor control when Tumor Treating Fields are used with PULSAR in glioblast...

A fast-growing body of research, both in vitro and in vivo, is converging to demonstrate the multiple inhibitory effects of Tumor Treating Fields on cancer growth The review article summarizes the known mechanisms of action of Tumor Treating Fields that have been reported by i...

Campaign urges healthcare providers to harness the versatile power of electric fields to outsmart solid tumors Novocure (NASDAQ: NVCR) today announced the launch of a campaign intended to drive awareness and understanding of Tumor Treating Fields (TTFields) therapy as a dist...

The number one fact in play right now for investors is risk aversion. According to Bank of America strategists, professional money managers are currently sitting on their highest cash allocation levels ever. According Sentimentrader.com, large investors are currently sitting on their largest ...

You only have to do two things to make a fortune investing in stocks. First, buy the right stock. Second, buy it at the right time. That's it. Unfortunately, those two simple steps can be very difficult to pull off. However, they don't always have to be so challenging. It's possible to ...

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2022 on Thursday, October 27, 2022, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results f...

As they enter the final quarter of calendar year 2022, many investors are probably wondering when the sell-off will end. This year has tested the patience of even the most experienced investors as the tech-heavy Nasdaq Composite is down over 30% from its all-time high while the S&...

Summary NovoCure faces a host of growth options along two key vectors: new geographies and other cancer applications. Despite short-term de-growth in active patients, long-term tailwinds to market share justify the company's superior multiple expansion. A conservative valuatio...